Crocs, Inc. (CROX) Stock Price & Analysis
Crocs, Inc. (CROX) closed at USD 120.99 on Thursday, October 22, 2026, up 2.11% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 118.49; the Oct 22, 2026 session ranged USD 117–121.26 on volume of 946,448 shares. Market capitalization is $5.80B, with a 52-week range of USD 73.21–141.28 (NMS). Source: Nexqual, retrieved October 23, 2026 at 09:16 UTC.
Also available as compact Markdown for AI agents: nexqual.com/CROX.md
Key facts (CROX)
- Last four reported quarters (through Jun 30, 2026): revenue $4.05B, net income $593M (14.6% margin), free cash flow $705M (SEC filings).
- Valuation: P/E 9.8x (avg 7.1x at the last 2 fiscal year-ends), EV/EBITDA 7.5x, net debt $1.14B.
- 6 of 80 tracked superinvestors hold CROX (13F, Q2 2026): 0 new, 1 added, 3 reduced, 2 unchanged.
- Insider open-market sales, last ~7 months: 2 Form 4 filings, $8.0M; 2 not under a Rule 10b5-1 plan ($8.0M); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Insider open-market purchases, last ~7 months: 3 Form 4 filings, $613K; 2 by opportunistic insiders, 0 by routine insiders.
- Analysts: Buy (mean 2.33 on a 1–5 scale) (15 analysts), mean target USD 138.75 (range 95–163).
- Total return with dividends: 1Y +42.1% vs S&P 500 +14.9%; 5Y -19.2% vs S&P 500 +80.3%.
- Next earnings: 2026-10-29, EPS estimate USD 3.31, revenue estimate $1.00B.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (CROX)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $2.31B | $3.55B | $3.96B | $4.10B | $4.04B | $4.05B |
| Gross profit | $1.42B | $1.86B | $2.21B | $2.41B | $2.36B | — |
| Operating income | $683M | $851M | $1.04B | $1.02B | $150M | $841M |
| Net income | $726M | $540M | $793M | $950M | -$81.2M | $593M |
| EPS (diluted) | $11.39 | $8.71 | $12.79 | $15.88 | -$1.50 | — |
| Free cash flow | $511M | $499M | $815M | $923M | $659M | $705M |
| Gross margin | 61.4% | 52.3% | 55.8% | 58.8% | 58.3% | — |
| Operating margin | 29.5% | 23.9% | 26.2% | 24.9% | 3.7% | 20.7% |
| Net margin | 31.4% | 15.2% | 20.0% | 23.2% | -2.0% | 14.6% |
| Revenue growth | +66.9% | +53.7% | +11.5% | +3.5% | -1.5% | — |
| Cash + short-term investments | $213M | $192M | $149M | $180M | $130M | — |
| Total debt | $771M | $2.32B | $1.66B | $1.35B | $1.23B | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (CROX)
P/E 9.8x · P/S 1.4x · EV/EBITDA 7.5x · EV/Sales 1.7x · P/FCF 8.2x · P/B 4.2x · FCF yield 12.15% · Earnings yield 10.23% · Buyback yield (TTM) 11.11% · Net debt $1.14B · EV $6.94B
P/E at fiscal year-ends: Dec 2024 6.9x, Dec 2023 7.3x.
Superinvestors (SEC 13F-HR, Q2 2026) (CROX)
6 of 80 tracked investors hold CROX. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Norbert Lou | Punch Card Management | 27.20% | $69.6M | Reduced -2.9% |
| Samantha McLemore | Patient Capital Management | 3.20% | $96.4M | Reduced -5.2% |
| Li Lu | Himalaya Capital Management | 2.89% | $107M | Unchanged |
| David Einhorn | Greenlight Capital | 2.07% | $80.7M | Unchanged |
| Bill Miller | Miller Value Partners | 0.82% | $3.5M | Reduced -25.1% |
| Tweedy Browne | 0.18% | $2.3M | Added +36.9% |
Insider sales (SEC Form 4, open-market, last ~7 months) (CROX)
0 of 2 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-08-07…2026-08-10 | Rees Andrew | Chief Executive Officer | 30,000 | $4.2M | 2.3% | No | Too little history (no open-market trades in 2025) |
| 2026-06-05 | Rees Andrew | Chief Executive Officer | 32,688 | $3.9M | 2.6% | No | Too little history (no open-market trades in 2025) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Insider purchases (SEC Form 4, open-market, last ~7 months) (CROX)
3 purchases, $613K. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.
| Trade date | Insider | Role | Shares | Value | Avg price | Insider type |
|---|---|---|---|---|---|---|
| 2026-09-15 | Smach Thomas J | Director | 680 | $76K | 111.49 | Opportunistic (traded every year 2023–2025, no repeating month) |
| 2026-09-15 | Kaplan Beth J | Director | 885 | $99K | 112.12 | Too little history (no open-market trades in 2023–2025) |
| 2026-09-10 | Smach Thomas J | Director | 4,000 | $438K | 109.38 | Opportunistic (traded every year 2023–2025, no repeating month) |
Analysts (CROX)
Consensus Buy (mean 2.33 on a 1–5 scale), 15 analysts; mean target USD 138.75 (low 95, high 163).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-15 | Barclays | Upgrade | Equal-Weight → Overweight | $118 → $139 |
| 2026-07-31 | UBS | Target raised | Neutral | $107 → $120 |
| 2026-07-31 | Barclays | Target raised | Equal-Weight | $110 → $118 |
| 2026-07-23 | B of A Securities | Target raised | Buy | $145 → $160 |
| 2026-07-20 | Seaport Global | Target raised | Buy | $135 → $160 |
| 2026-06-26 | Piper Sandler | Upgrade | Neutral → Overweight | $95 → $150 |
Total return (dividends reinvested) (CROX)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +42.1% | -19.2% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +42.3% | -4.2% |
| Volatility (annualized) | 43.6% | 52.5% |
| Max drawdown | -24.3% (Feb 2026→Mar 2026) | -73.9% (Nov 2021→Jun 2022) |
CROX revenue by business segment (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Crocs Brand | $1.00B | 84.8% | +4.3% |
| HEYDUDE Brand | $179.0M | 15.2% | -5.7% |
| Total revenue | $1.18B | 100% | — |
CROX revenue by region (fiscal year ended Dec 31, 2025)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| United States | $2.26B | 55.9% | -8.9% |
| Non Us | $1.78B | 44.0% | +9.9% |
| Total revenue | $4.04B | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
CROX suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Supplier | Xinjiang Production and Construction | “Even if we were not subject to penalties, fines or sanctions, if products we source are linked in any way to XPCC, the XUAR, or an entity on the UFLPA entity list, our reputation could be damaged.” |
Quoted from the company's 10-K filed Feb 12, 2026.
Companies that name CROX in their SEC reports
| Relationship to CROX | Company | Filing | Sentence |
|---|---|---|---|
| customer | SHOE STATION GROUP INC (SHOE) | 10-K Mar 26, 2026 | “Three branded suppliers, Nike, Skechers and Crocs, collectively accounted for approximately 46% of our Net Sales in Fiscal 2025, 48% of our Net Sales in Fiscal 2024 and 45% of our Net Sales in Fiscal 2023.” |
CROX company outlook (results filed Jul 30, 2026)
- “Outlook • Full-Year 2026 Outlook Raised On Both The Top- And Bottom-Line • Crocs Brand Surpasses $1 Billion In Quarterly Revenue For The First Time • Share Repurchase Authorization Increased By $1.5 Billion To Approximately $2 Billion ___________________________________________________________________________ BROOMFIELD, COLORADO — July 30, 2026 — Crocs, Inc.”
- “(NASDAQ: CROX), a world leader in innovative casual footwear for all, today announced its second quarter 2026 financial results. "We are pleased to have delivered a stronger-than-expected second quarter, highlighted by record enterprise revenue, including the Crocs Brand surpassing $1 billion in quarterly revenue for the first time ever.”
Quoted word-for-word from the SEC 8-K results press release.
CROX analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $3.31 | $3.55 | -6.7% | $1.00B | 14 |
| Next quarter (ends Dec 2026) | $3.12 | $2.85 | +9.6% | $994.6M | 13 |
| Current fiscal year (ends Dec 2026) | $13.97 | $13.68 | +2.1% | $4.10B | 15 |
| Next fiscal year (ends Dec 2027) | $15.01 | $14.54 | +3.2% | $4.20B | 15 |
CROX options: expected move
Options price a move of about ±14.8% (±$17.65) by Nov 20, 2026, which includes earnings on Oct 29, 2026. Over the last 8 reports the stock moved ±13.6% on average.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 28 | 65.1% | ±14.8% |
| Dec 18, 2026 | 56 | 50.8% | ±16.2% |
| Jan 15, 2027 | 84 | 49.8% | ±19.3% |
| Mar 19, 2027 | 147 | 48.7% | ±24.9% |
| Jun 17, 2027 | 237 | 48.9% | ±31.5% |
| Sep 17, 2027 | 329 | 47.0% | ±35.5% |
30-day implied volatility 60.8% vs 40% realized over the last 30 trading days. Put/call ratio (volume) 0.75. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 09:16 UTC)
| Price | USD 120.99 |
|---|---|
| Change | ▲ 2.11% (up) |
| Previous Close | USD 118.49 |
| Open | USD 117.13 |
| Day Range | USD 117 – 121.26 |
| 52-Week Range | USD 73.21 – 141.28 |
| Volume | 946,448 shares |
| Market Cap | $5.80B |
| Exchange | NMS |
Technical Analysis (CROX)
Nexqual's technical model rates CROX "STRONG BUY" based on 5 bullish and 0 bearish signals across 127 daily candles, as of October 23, 2026 at 09:16 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 53.02 (neutral) |
| vs SMA50 | Above (USD 120.28) |
| MACD | 0.01 (positive) |
Analyst Ratings (CROX)
Wall Street analysts rate CROX "Buy" based on 15 analysts, with a mean price target of USD 138.75 (range USD 95–163), per Nexqual as of October 23, 2026 at 09:16 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 15 |
| Mean Target | USD 138.75 |
| High Target | USD 163 |
| Low Target | USD 95 |
| Buy / Hold / Sell | 8 / 6 / 1 |
Earnings (CROX)
| Next Earnings Date | 2026-10-29 |
|---|---|
| EPS Estimate | USD 3.31 |
| Revenue Estimate | $1.00B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 4.55 vs est 4.35 ▲ beat |
| 2026-03-31 | USD 2.99 vs est 2.79 ▲ beat |
| 2025-12-31 | USD 2.29 vs est 1.91 ▲ beat |
| 2025-09-30 | USD 2.92 vs est 2.36 ▲ beat |
Source: Nexqual, October 23, 2026 at 09:16 UTC.
Financials & Fundamentals (CROX)
| Total Revenue | $4.05B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +2.60% |
| Gross Margin | +57.47% |
| Operating Margin | +24.22% |
| Profit Margin | +14.64% |
| ROE | +42.30% |
| Debt / Equity | 1.22 |
| Current Ratio | 1.49 |
| Total Cash | $170.28M |
| Total Debt | $1.69B |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | $704.62M (17.4% of revenue) |
Source: Nexqual, October 23, 2026 at 09:16 UTC.
Financial Health Score (CROX)
Nexqual rates Crocs, Inc.'s overall financial health "Solid" across five dimensions, as of October 23, 2026 at 09:16 UTC.
| Growth | Weak — Revenue -1% YoY (annual), declining |
|---|---|
| Profitability | Strong — Gross margin 57%, operating 24% (last 12 months) |
| Balance Sheet | Mixed — $170M cash and investments vs $1.31B debt (Jun 2026, SEC) |
| Cash Flow | Strong — FCF $705M (last 4 quarters to Jun 2026, SEC), 17% margin |
| Efficiency | Strong — ROE 42%, ROA 12.0% |
Ownership (CROX)
| Insider Ownership | +3.10% |
|---|---|
| Institutional Ownership | +103.60% |
| Shares Outstanding | 47.95M |
| Float | 46.12M |
| Short % of Float | +14.00% |
Source: Nexqual, October 23, 2026 at 09:16 UTC.
Leadership (CROX)
Crocs, Inc. is led by Andrew Rees, CEO & Director, per Nexqual as of October 23, 2026 at 09:16 UTC.
| CEO & Director | Andrew Rees |
|---|---|
| Executive VP & CFO | Patraic Reagan |
| Executive VP & Brand President for Crocs | Anne Mehlman |
| Executive VP & President of the Heydude Brand | Rupert Campbell |
| Senior Vice President of Global Sourcing & Product Execution | Erik Olson |
Major Backers & Investors (CROX)
Notable institutional backers of Crocs, Inc. include FMR, LLC, LSV Asset Management, American Century Companies Inc, according to Nexqual as of October 23, 2026 at 09:16 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FMR, LLC | 7.32% |
| LSV Asset Management | 3.78% |
| American Century Companies Inc | 3.07% |
| Fuller & Thaler Asset Management Inc. | 2.71% |
| Capitol Series Trust-FullerThaler Behavioral Small-Cap Equity Fund | 2.58% |
| Citadel | 2.29% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 9.7% |
| Vanguard Group | 8.89% |
| State Street | 3.31% |
| Dimensional Fund Advisors | 2.47% |
Source: Nexqual, October 23, 2026 at 09:16 UTC.
From Crocs, Inc.'s Latest SEC 10-K Filing (filed 2026-02-12)
Key Strengths & Strategy (as disclosed to the SEC)
- Croslite™, our proprietary closed-cell resin material, incorporates the primary material formulations used in the vast majority of our Crocs Brand footwear and some of our accessories.
- Our company-operated full-price retail stores allow us to effectively showcase the full extent of our product range to consumers and provide us with the opportunity to interact with those consumers directly.
- Our company-operated outlet stores allow us to sell discontinued and overstocked merchandise directly to consumers at discounted prices.
- Our company-operated kiosks and store-in-store locations allow us to market specific product lines, with flexibility to tailor products to consumer preferences in shopping malls and other high foot-traffic areas.
Partnerships
- With efficient use of retail space and limited fixed cost and capital investment, we believe kiosks and store-in-store locations can be effective vehicles for selling our products in certain geographic areas.
Legal & Regulatory Risks (Item 1A, quoted)
- Our third-party manufacturing operations must comply with labor, trade, and other laws. Failure to do so may adversely affect us.
- Government actions and regulations, such as export restrictions, tariffs, and other trade protection measures, could adversely affect our business.
- Our business relies significantly on the use of information technology. A significant disruption to our operational technology or those of our business partners, a privacy law violation, or a data security breach could harm our reputation and/or our ability to effectively operate our business, and our financial results.
- We are subject to periodic litigation, which could result in unexpected expenditures of time and resources.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BIRK | Birkenstock Holding plc | USD 33.68 | ▲ 4.21% |
| SHOO | Steven Madden, Ltd. | USD 44.42 | ▼ 0.6% |
| ONON | On Holding AG | USD 34 | ▼ 0.64% |
| DECK | Deckers Outdoor Corporation | USD 85.28 | ▼ 0.25% |
| WWW | Wolverine World Wide, Inc. | USD 20.68 | ▲ 2.83% |
| NKE | Nike, Inc. | USD 38.32 | ▲ 2.1% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:16 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt